Pfizer on Wednesday forecast 2024 revenue that was below Wall Street expectations and raised its cost-cut target by $500 million.
The U.S. drugmaker expects its annual revenue to be in the range of $58.5 billion to $61.5 billion compared with analysts' average estimate of $63.17 billion. It includes the contribution from sales of Seagen's products.
Pfizer shares tumbled over 9% on the news.
Sales of Paxlovid and the vaccine Pfizer makes with German partner BioNTech had boosted revenue over the last two years, helping it generate more than $100 billion in 2022.
But a drop in annual vaccination rates and demand for the treatments have forced the company to launch a program in October to cut jobs and expenses to save as much as $3.5 billion.
The company, which employs roughly 83,000 employees globally, in November cut 500 jobs at its Sandwich, Kent site in the UK.